Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Dr. Adel Nada leads the development of NBS-03, NeoStem’s proprietary autologous expanded regulatory T-cell platform, in autoimmunity and allergy indications, including type 1 diabetes. Before coming to NeoStem, Dr. Nada led the clinical development of Baxter’s autologous CD34+ cell therapy for a variety of cardiovascular indications, and was responsible for the Phase 3 program in chronic myocardial ischemia. Before then, Dr. Nada led the Clinical Pharmacology Medical Department at Abbott Laboratories, which provided strategic and technical guidance to Abbott’s early clinical development pipeline across all therapeutic areas, and was responsible for the cardiac safety and clinical pharmacogenetics organizations.
In addition, Dr. Nada was the medical director for Abbott’s immunology project team developing a novel investigational agent for rheumatoid arthritis.
http://www.endocrineweb.com/author/13137/nada
EVA Dimensions, LLC upgrades NEOSTEM INC from HOLD to OVERWEIGHT.
BY Investars Analyst Actions - public
— 9:04 AM ET 03/31/2015
On March 31, 2015 EVA Dimensions, LLC upgraded NEOSTEM INC ( NBS Research ) from HOLD to OVERWEIGHT.
David Nazar from PBS interviews Dr. Hans Keirstead.
"Intus is latin for 'from within'".
This is only a 2 minute video everybody needs to watch!! I do not know why Neostem has not had his published out all over because it is really good! The date on this is 3/27/2015 It has been out a week!!!! http://video.pbssocal.org/video/2365452306/
Up 5% after hours, we are at 2.75 up 13 cents? We had a high of $2.88 afterhours anybody hear anything yet?? Something is up!! You can go here and see the after hours trading over 25 thousand shares traded, 5,000 where traded over $2.80? Right at the end of the day all a sudden the price went green? http://www.nasdaq.com/symbol/nbs/after-hours
You know we have ties to Abbott, does anyone think that the sale of 31% of their holdings in Maylan, which would raise 1.99 billion dollars, that some of that might be headed Neostem's way?? http://www.thestreet.com/story/13098501/1/mylan-myl-stock-is-down-today-after-pricing-secondary-offering.html?puc=yahoo&cm_ven=YAHOO
If you have not yet you need to go here and look at the slide presentation at the bottom of the page! Very impressive, especially if you look at slide 5 you will see our clients! Things will get better! http://www.neostem.com/investors/overview/
Friday June 26th. Table 7, Hans Keirstead, PhD
NeoStem Oncology, United States.
http://www.isscr.org/home/annual-meeting/isscr2015/program/junior-investigator-events/meet-the-experts-luncheon Friday June 26th with Hans Keirstead, PhD >>>>
Expertise: Dr. Keirstead is President of NeoStem Oncology and is an internationally known stem cell expert with extensive basic research and clinical experience. He has developed stem cell-based therapies for late stage cancers, motor neuron diseases, spinal cord injury and retinal diseases.
Carl J. Pepine, MD
Carl J. Pepine
•
PreSERVE-AMI represents the first cell-therapy trial to show a reduction in mortality with administration of CD34+ cells. A unique aspect of this trial is that the investigators used high-dose CD34+ cells. In addition, patients enrolled in this trial had among the lowest baseline ejection fractions of the cell-therapy trials. The investigators did link the CD34+ cell number with a number of the outcomes. We previously published that using mobilized CD34+ cells in patients with refractory angina markedly reduced angina frequency and had a strong trend (P=.058) toward reduction in death or MI at 1 year (Losordo DW. Circ Res. 2011;109:428-436). It seems like this study too is zeroing in on something important for the CD34+ cells in ischemic heart disease. I would like to see more trials on this. All of these data are starting to fit together as important and the PreSERVE-AMI results will rejuvenate the cell therapy field.
Carl J. Pepine, MD
Chief Medical Editor, Cardiology Today
NeoStem (NBS) Enters Oversold Territory - Tale of the Tape
Zacks By Zacks Equity Research
1 hour ago
NeoStem Inc (NBS) has been on a bit of a cold streak lately, but there might be light at the end of the tunnel for this overlooked stock. And for technical investors there is some hope when looking at NBS given that, according to its RSI reading of 26.52, it is now in oversold territory.
What is RSI?
RSI stands for ‘Relative Strength Index’ and it is a popular indicator used by technically focused investors. It compares the average of gains in days that closed up to the average of losses in days that closed down; readings above 70 suggest an asset is overbought, while an RSI below 30 suggests undervalued conditions are present.
Other Factors
Yet, NBS’s low RSI value isn’t the only reason to have some optimism over a coming turnaround, as there has been plenty of positive earnings estimate revision activity as of late. This is especially true when investors take a deep dive into some of these estimate revision stats and recent changes to NeoStem’s earnings consensus.
Over the past two months, investors have seen 1 earnings estimate revision moved higher, compared with none lower, at least when looking at the key current year time frame. And the consensus estimate for NBS has also been on an upward trend over the past 60 days, as estimates have risen from -$1.8/share two months ago to just -$1.77/share right now.
If this wasn’t enough, NeoStem also has a Zacks Rank #2 (Buy) which puts it into rare company among its peers. So, given all of these factors, investors may want to consider getting in on this stock now (or holding on), as there are some favorable trends that could bubble up for this stock before long.
You know we are funded to start Intus study don't you? We 15 million to start and another 5 million disbursement is available in the event of the Company’s consummation of a partnering transaction around the Company’s NBS10 development program for post acute myocardial infarction (“AMI”) patients. Folks we are in real good shape!! http://www.neostem.com/media/press-releases/news-item/neostem-secures-debt-facility/
This looks really good for those that did not catch this video here it is! Underneath the video you can read what was said! http://www.medscape.com/viewarticle/838795?src=wnl_edit_specol&uac=214680FY#vp_3
Thank You
YES Oppenheimer Starts coverage on NBS as OUTPERFORM!! http://www.streetinsider.com/Analyst+Comments/Oppenheimer+Starts+NeoStem+%28NBS%29+at+Outperform/10151785.html
Does anybody read my posts? LOL If so please let me know, if not I do not think I will post here anymore.
PCT is continuing work on CAR T-Cells, Adoptive immunotherapies, T-Cell therapies, dendritic vaccines in the next wave of oncological development. Turning personaized cells into immunotherapies is PCT's expertise. Here's a little PCT history for you and a glimpse of why the innovation should also continue.
http://www.pharmpro.com/articles/2014/07/getting-very-personal-pct-story?et_cid=4038084&et_rid=461894883&type=cta
Add Kidney cancer to the pipeline! https://clinicaltrials.gov/ct2/show/NCT00014131?term=dillman+dendritic+phase2&rank=4
Does anybody realize we have this going on also?? https://clinicaltrials.gov/ct2/show/NCT02033616?term=dillman&rank=6
This is a article about cancer! http://www.sciencemag.org/content/347/6217/78 Do you realize we are in Phase 3? Look here http://www.neostem.com/research-and-development/therapeutic-targets/targeted-immunotherapy-program/ there is also a video on youtube that explains how this works!
KITE before you knew they were going to be worth $3 Billion.
Uses this stem cell companies product! http://www.neostem.com/media/press-releases/news-item/pct-kite-pharma/
Did you know KITE before you knew they were going to be worth $3 Billion.
http://www.neostem.com/media/press-releases/news-item/pct-kite-pharma/ NeoStem was there!! I do not think a lot of people realize how involved NeoStem is in the stem cell field and helping other Stem Cell companies buy them using NEOSTEMs products!
This is so much BS http://finance.yahoo.com/news/investor-alert-law-firm-levi-185100409.html If you notice it came out at our top PPS for the day $3.90! It is a INVESTIGATION not a lawsuit! What kills me is they could have investigated within a few hours because all sec filings and contracts are PUBLIC! They announced to bring the stock down, why wouldn't you investigate then sue when you have proof! IMHO this is a short attack by a ambulance chasing law firm who if you google has been putting these INVESTIGATIONS on a lot of Bios lately! All this is in SEC filings and very easy to check!
Read this http://www.dovepress.com/melanoma-vaccines-trials-and-tribulations-peer-reviewed-article-VDT If you do not know who Robert O. Dillman, MD is you need to read this:: Vice President, Oncology
Dr. Robert O. Dillman, served as CSC’s Chief Medical Officer prior to the CSC Acquisition, and now holds the title of NeoStem’s Vice President, Oncology.
Dr. Dillman has served as the Executive Medical Director of the Hoag Hospital Institute for Research and Education, in Newport Beach, California, a position he has held since 2011. Prior to this position he served as Executive Medical Director of the Hoag Family Cancer Institute from 2008-2011, and was Medical Director of the Hoag Cancer Center from 1989-2008. He has also served as a Clinical Professor of Medicine at the University of California, Irvine (“UCI”) since 1989. Dr. Dillman chaired the Cancer Biotherapy Research Group from 1990 to 2002, and is a past President and board Member of the International Society for Immunotherapy of Cancer.
Dr. Dillman has directed a cell biology research laboratory focused on patient-specific cell therapies for more than 20 years. He is an internationally recognized leader in cancer immunotherapy approaches, including monoclonal antibodies, adoptive cell therapies, IL-2, and cancer vaccines. He has authored more than 300 medical publications and is recognized internationally for his work in lung cancer, lymphoma, Chronic Lymphocytic Leukemia (CLL), melanoma, and kidney cancers. He was the first physician in Orange County, California to be selected as one of the Best Doctors in America in Hematology and/or Oncology. In 2006, Dr. Dillman was named Orange County Physician of the Year by the Orange County Medical Association. In 2008, he received Hoag Hospital’s first endowed chair, the Grace E. Hoag Endowed Chair of Oncology and in 2010, he became one of only five recipients in the world to receive the Distinguished Service Award from the Society for Immunotherapy of Cancer.
Dr. Dillman received his undergraduate degree from Stanford University and medical degree from Baylor College of Medicine. He also completed both his internship and residency in Internal Medicine at Baylor College of Medicine, and served as a Chief Resident. He completed his fellowship in Hematology/Oncology at University of California, San Diego Medical Center.
2015 outlook for Bios, they have a nice read on NBS! http://www.thelifesciencesreport.com/pub/na/will-biotech-fire-on-all-cylinders-in-2015
Dr. Robin Smith THANK YOU for your contributions to NBS! Here are some of her accomplishments http://www.thechairmansblog.com/neostem/management/
Neostem to present January 12 2015 http://www.ebdgroup.com/bts/presenters/prs_comps.php
New sec filings dated Jan 05, 2015 http://www.nasdaq.com/symbol/nbs/sec-filings
Here is the Interview with Robin and Larsado from ""The New To The Street""